

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Image 1642

Applicant: John H. Petrini et al.

Title: ANTIBODY SPECIFIC FOR A DNA REPAIR PROTEIN

Docket No.: 800.019US4

Serial No.: 10/044,447

Filed: January 10, 2002

Due Date: N/A

Examiner: Unknown

Group Art Unit: 1642

Customer No.: 21186

Confirmation No.: 9054

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):


☒ A return postcard.

☒ A Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (1 pg.). Documents NOT enclosed, cited in parent application.

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186

By: 
Atty: Janet E. Embreyson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 13th day of November, 2003.

Gulim Abilova
Name

Gulim Abilova
Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
(GENERAL)

Customer Number 21186



S/N 10/044,447

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	John H. Petrini et al.	Examiner:	Unknown
Serial No.:	10/044,447	Group Art Unit:	1642
Filed:	January 10, 2002	Docket:	800.019US4
Title:	ANTIBODY SPECIFIC FOR A DNA REPAIR PROTEIN		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

Pursuant to 37 C.F.R. §1.98(d), copies of the listed documents are not provided as these references were previously cited by or submitted to the U.S. Patent Office in connection with Applicants' prior U.S. application, Serial No. 09/837,138, filed on April 18, 2001, which is relied upon for an earlier filing date under 35 U.S.C. §120.



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No :10/044447

Filing Date: January 10, 2002

Title: ANTIBODY SPECIFIC FOR A DNA REPAIR PROTEIN

Page 2

Dkt: 800.019US4


The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

JOHN H. PETRINI ET AL.


By their Representatives,


SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date November 12, 2003 By 
Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 12th day of November, 2003.

Gulim Abilova
Name


Signature



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/044,447
Filing Date	January 10, 2002
First Named Inventor	Petrini, John
Group Art Unit	1642
Examiner Name	Unknown

Sheet 1 of 1

Attorney Docket No: 800.019US4

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	US-6,458,534	05/27/1998	Concannon, Patrick, J., et al.	435	6	04/27/1999

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
--------------------	---------------------	------------------	---	-------	----------	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ECK, S. L., et al., "Gene-Based Therapy", In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, Chapter 5, McGraw-Hill, Health Professions Division, New York, (1996), 77-101	
		HOUDEBINE, L., "Production of Pharmaceutical Proteins From Transgenic Animals", Journal of Biotechnology, Vol. 34, France, (1994), 269-287	
		ORKIN, S. H., et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy", National Institutes of Health, Entire Document, (Dec. 7, 1995), 40 pages	
		VERMA, I. M., et al., "Gene Therapy Promises, Problems and Prospects", Nature, Vol. 389, (18 Sep. 1997), 239-242	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached